Tag:

Johnson & Johnson

Latest Headlines

Latest Headlines

Boston Scientific down on disclosure of subpoena about Bridgepoint acquisition

A Securities and Exchange Commission filing from Aug. 6 disclosed that Boston Scientific received a subpoena from the U.S. Attorney for the District of New Jersey regarding its acquisition of Bridgepoint Medical, leading to a sharp decline in trading. 

J&J Baby aims to turn ingredients scandal into sales with 'transparent' ad campaign

Under pressure from consumer groups, Johnson & Johnson vowed to remove certain controversial ingredients from its baby and infant products two years ago. Now, the company is taking that oath and turning it into a marketing advantage.

Physicians weigh in on J&J power morcellator recall

Days after Johnson & Johnson pulled its devices for minimally invasive hysterectomies from the global market, physicians are shedding light on alternative surgical methods and questioning the recall's implications for women undergoing the procedure.

Johnson & Johnson pulls power morcellator devices amid industry and regulatory backlash

Amid regulatory and industry backlash surrounding the use of laparoscopic surgical tools in gynecological procedures, Johnson & Johnson is pulling its related device from the global market.

NuVasive grabs spinal market share, beats Wall Street expectations and gains 10%

Spinal device specialist NuVasive said it's third in the spinal device market and is aiming now for second place along with more than $1 billion in annual revenue. Wall Street ate up that news, along with an earnings beat and raised guidance, and chased the stock up 10% in early trading on June 30.

J&J, Pharmacyclics celebrate yet another nod for leukemia med Imbruvica

Johnson & Johnson's new blood cancer drug Imbruvica (ibrutinib) is on a roll. The FDA just armed the drug with a new indication in chronic lymphocytic leukemia, adding to a series of regulatory nods.

Pfizer, Lilly and J&J chip in on $51M seed fund for New York biotechs

Three Big Pharma companies have helped come up with some seed money to start growing the first crop of biotechs in New York. Pfizer, Eli Lilly and J&J all chipped in to a $51 million fund from Accelerator Corp., which will now expand on the work it's been doing in Seattle to the East Side of Manhattan, recruiting upstarts to join investigators at the Alexandria Center for Life Science.

Janssen rethinks drug discovery in a changing R&D environment

For William Strohl, the new head of Janssen's Biotechnology Center of Excellence, the future of drug R&D involves novel targets, "fit-for-purpose" antibodies and lots of collaborations.

J&J builds 9-month supply of Doxil with creative problem solving

A Johnson & Johnson exercise in creative problem solving has paid off for doctors and patients who rely on its ovarian cancer drug Doxil, availability of which has been uncertain for years. Its Janssen unit has accumulated a significant supply after assuming manufacturing at Boehringer Ingelheim plant that otherwise was closed down at the end of the year.

Gilead's Zydelig, J&J's Imbruvica will go toe-to-toe in EU with nod for CLL

Gilead Sciences, which this week got FDA approval for its new blood cancer drug Zydelig (idelalisib), has now gotten a recommendation for its use in Europe. But competitor Imbruvica from Johnson & Johnson, which got a head start in the U.S., also received a nod from EU authorities today.